Table 1. Patient characteristics and response to treatment at 6 weeks.
| Characteristic | SO/ER | BV/ER | ER |
|---|---|---|---|
| N (%) | N (%) | N (%) | |
| Total | 25 | 18 | 10 |
| Sex | |||
| Male | 14 (44) | 12 (67) | 4 (40) |
| Female | 11 (56) | 6 (33) | 6 (60) |
| Median age (years) (range) | 60 (41–78) | 63 (34–80) | 68 (59–77) |
| Smoking status | |||
| Current or former smoker | 20 (80) | 18 (100) | 9 (90) |
| Non-smoker | 5 (20) | 0 | 1 (10) |
| ECOG performance status | |||
| 0 | 17 (68) | 5 (28) | 2 (20) |
| 1 | 8 (32) | 9 (50) | 7 (70) |
| 2 | 0 | 4 (22) | 1 (10) |
| Tumour histology | |||
| Adenocarcinoma | 18 (72) | 12 (67) | 5 (50) |
| Large cell | 2 (8) | 5 (28) | 4 (40) |
| Squamous cell | 1 (4) | 0 | 1 (10) |
| BAC | 2 (8) | 1 (6) | 0 |
| NSCLC NOS | 2 (8) | 0 | 0 |
| Tumour stage | |||
| IIIB | 7 (28) | 5 (28) | 1 (10) |
| IV | 18 (72) | 13 (72) | 9 (90) |
| Previous treatment | |||
| Yes | 2 (8) | 0 | 5 (50) |
| No | 23 (92) | 18 (100) | 5 (50) |
| Response at 6 weeks | |||
| Partial response | 10 (40) | 4 (22) | 0 |
| Stable disease | 12 (48) | 10 (56) | 8 (80) |
| Progressive disease | 3 (12)a | 4 (22) | 2 (20) |
| Response at 6 weeks corrected for cavitations | — | — | |
| Partial response | 13 (52) | ||
| Stable disease | 9 (36) | ||
| Progressive disease | 2 (8)a | ||
| Median time to progression, months (95% CI) | 6.0 (11.7–13.2) | 6.8 (3.2–10.3) | 6.6 (2.6–10.7) |
| Median survival, months (95% CI) | 12.5 (11.7–13.2) | 6.9 (5.4–8.3) | 6.0 (0–12.8) |
Abbreviations: BAC=bronchioloalveolar carcinoma; BV=bevacizumab; ECOG=Eastern Cooperative Oncology Group; ER=erlotinib; SO=sorafenib.
a
One PD patient had no formal evaluation for treatment response because of early off study due to treatment-related toxicity.